[Skip to Content]
[Skip to Content Landing]
August 1981

Topical Clindamycin Therapy for Acne VulgarisA Cooperative Clinical Study

Author Affiliations

From the University of New Mexico, Albuquerque (Dr Becker); the University of Texas, Dallas (Drs Bergstresser and Whiting); Hitchcock Clinic, Hanover, NH (Dr Clendenning); the State University of New York, Buffalo (Dr Dobson); the Medical College of Virginia, Richmond (Drs Jordan and Abell); the Puerto Rico Medical Center, Rio Piedras (Dr LeZotte); Boston University (Dr Pochi); New York University (Dr Shupack); Scripps Clinic Medical Group Inc, La Jolla, Calif (Dr Sigafoes); the University of California, San Diego (Dr Stoughton); the University of Michigan, Ann Arbor (Dr Voorhees).

Arch Dermatol. 1981;117(8):482-485. doi:10.1001/archderm.1981.01650080036024

• Eleven institutions participated in an eight-week controlled clinical study to evaluate treatment of acne vulgaris with topical clindamycin hydrochloride and clindamycin phosphate. Three hundred fifty-eight patients with comparable baseline pustule, papule, and nodule counts applied 1% clindamycin hydrochloride, 1% clindamycin phosphate, or a hydroalcoholic vehicle twice daily. Every two weeks, lesions were counted, and patients' evaluations of their acne conditions were scored. By week 8, pustule and papule counts in the groups who were receiving clindamycin were significantly lower than those in the group receiving placebo. Also, more patients who were receiving clindamycin thought their acne improved by week 8 (with significantly higher change-in-acne scores) than did the patients receiving placebo. Patients receiving clindamycin reported 12 episodes of diarrhea; only one episode was considered to be treatment related. These results substantiate the clinical impession that topical clindamycin is effective treatment for acne.

(Arch Dermatol 1981;117:482-485)